Redeye leaves a comment following Alzinova’s announcement that the FDA has granted Fast Track Design...
Redeye updates its estimates and valuation after Mendus’ clinical strategy update.
In a preliminary release ahead of its full report on 24 October 2025, AVTECH announced Q3 2025 net s...
Redeye endorses the news that Egetis has secured cSEK183m in a directed issue and give our initial t...
Redeye kommenterar nedläggningen av ”Project Baxter”, som vi tror var rätt beslut givet förutsättnin...
Redeye comments on the termination of “Project Baxter”, which we believe was the right decision give...
Redeye is optimistic after Hansa’s directed share issue tonight, which was expanded from USD60m to U...
Redeye comments on Mendus announcing a clinical strategy update, communicating its aim to address br...
Ahead of Enea's Q3 report on 23 October 2025, Redeye is raising its network estimate, buoyed by a ne...
Vi inleder bevakning på HomeMaid, ett av Sveriges ledande städbolag med över 1 300 anställda och ver...
Redeye comments on Nanologica’s press release confirming its first production-evaluation order for i...
* Report out on 17 October * Q3e sales SEK 48m, EBIT SEK -0.
Redeye is positive about Corline’s new licensing and supply agreement with Kardium, which underlines...
Redeye leaves a short comment on CLS’s fully subscribed warrants program (TO8B).
* Q3e: 11% organic sales growth, 10% adj. EBITA margin * We lower estimates on continued lack of upf...
Redeye comments on Heliospectra’s proposed SEK49.5m rights issue, partly secured by main shareholder...
* Q3'25 numbers due on 5 November at 07:45 CET * Adj.
* We expect an uneventful Q3 * Q3e net sales of SEK 179m, EBITA of SEK 29m * We reiterate our SEK 36...
Nettoomsättningen uppgick till 52,2 MSEK (49,2) i det första kvartalet (maj-jul) i Vuxen Groups brut...
* Up to SEK 930m order from the US on Intercom and Link wireless products * SEK 25m order to be book...
